Keyphrases
Sepsis
100%
Burkholderia Pseudomallei
100%
Outer Membrane Vesicle Vaccines
100%
Outer Membrane Vesicles
100%
Pseudomallei
80%
Immunization
40%
Melioidosis
20%
Immune Serum
20%
High Morbidity
10%
High Mortality
10%
Mortality Rate
10%
Antibody Response
10%
Select Agent
10%
Lethality
10%
Vaccine Development
10%
IgM Antibody
10%
Gram-negative Bacteria
10%
Systemic Infection
10%
Vaccine Strategy
10%
Balb C Mice
10%
Lipopolysaccharide
10%
Disease-associated
10%
Protein Antigen
10%
Multivalent
10%
Causative Agents
10%
Morbidity Rate
10%
Gram-negative
10%
Protective Efficacy
10%
Multivalent Vaccine
10%
Capsular Polysaccharide
10%
Bacterial Killing
10%
South-East Asia
10%
Bacillus
10%
Passive Transfer
10%
Antibody-mediated Protection
10%
IgG1
10%
Serum IgG
10%
Innate Resistance
10%
Intraperitoneal Challenge
10%
Aerosol Challenge
10%
IgG2a
10%
IgG3
10%
Multiple Proteins
10%
Resistance to Antibiotics
10%
Polysaccharide Antigen
10%
Northern Australia
10%
Lipid Antigens
10%
Protein-polysaccharide Complexes
10%
Medicine and Dentistry
Membrane Vesicle
100%
Sepsis
100%
Outer Membrane
100%
Burkholderia pseudomallei
100%
Antiserum
18%
Polysaccharide
18%
Melioidosis
18%
Diseases
18%
Mortality Rate
9%
In Vitro
9%
Infection
9%
Gram-Negative Bacteria
9%
Antibody Response
9%
Lipopolysaccharide
9%
Vaccine Development
9%
Immunoglobulin M Antibody
9%
Lethality
9%
Immunoglobulin G3 Antibody
9%
Immunoglobulin G2a
9%
Immunoglobulin G1
9%
Bactericidal Activity
9%
Antibiotics
9%
Immunology and Microbiology
Membrane Vesicle
100%
Outer Membrane
100%
Burkholderia pseudomallei
100%
Antiserum
18%
Infection
18%
Antibody Response
9%
Mortality Rate
9%
Immunoglobulin M Antibody
9%
Gram-Negative Bacteria
9%
Bagg Albino Mouse
9%
Bactericidal Activity
9%
Immunoglobulin G1
9%
Immunoglobulin G2a
9%
Immunoglobulin G3 Antibody
9%
In Vitro
9%